Remove Bioinformatics Remove Research Remove RNA
article thumbnail

Case study: gget’s new Open Target module

The Open Targets Blog

  “Sam has an exceptional talent in software engineering, and his contributions reflect a deep understanding of both the technical and biological aspects required for bioinformatics tool development,” says Laura Luebbert, now a postdoctoral fellow in the Sabeti lab at the Broad Institute of MIT and Harvard and Harvard University.

article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

In drug discovery and biological research, the scientists workflow often follows a structured and iterative approach to ensure accuracy, reproducibility and scientific integrity. At the heart of any research is the scientific question. This acts as a safeguard against false positives and misinterpretation of the data.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

This second ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members of the drug discovery community to explore the discovery, validation, and targeting of oligonucleotide-based drug candidates, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).

RNA 59
article thumbnail

LINC00460 knockdown sensitizes cervical cancer to cisplatin by downregulating TGFBI

Chemical Biology and Drug Design

The prognostic value of long noncoding RNA (lncRNA) LINC00460 has been reported in cervical cancer. In present study, LINC00460 was screened out through bioinformatics analysis. Abstract The acquired resistance of cancer to cisplatin (DDP) limits the efficacy of chemotherapy.

article thumbnail

Reaching cruising altitude: New discovery tools to target RNA

Dark Matter Blog

However, since most small molecule drugs target proteins in the cell, the vast majority of target identification methods available to research scientists are aimed at identifying interactions between small molecules and proteins. First, given an RNA target, could we identify where on the RNA an rSM bound?

RNA 52
article thumbnail

IGF2BP3 loss inhibits cell progression by upregulating has_circRNA_103820, and hsa_circRNA_103820?encoded peptide inhibits cell progression by inactivating the AKT pathway in lung cancer

Chemical Biology and Drug Design

Abstract N6-methyladenosine (m6A) modification and m6A-related RNA-binding proteins (RBPs) play vital roles in various aspects of circRNA metabolism. Moreover, bioinformatics analysis has suggested that hsa_circRNA_103820 possesses potential peptide-coding ability.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures.